Stelara Impresses With Efficacy Data and Dosing Convenience, But Safety Concerns Likely to Impact Near Term Uptake

EXTON, Pa., Feb. 18 /PRNewswire/ -- BioTrends published the second wave of LaunchTrends^®: Stelara, highlighting dermatology market trends at three months post launch.  The report is based on 76 survey responses and 20 qualitative phone interviews with U.S. dermatologists.

About one-third of the survey respondents reported trial with Stelara which is a similar rate to Wave 1.  However, prescribing dermatologists report a higher number of patients on Stelara in the current wave compared to the prior period.  Stelara receives high ratings among dermatologists for efficacy attributes and dosing convenience attributes.  Obstacles to Stelara adoption include concerns about long term safety which are exacerbated by the recent withdrawal of Genentech/Xoma's Raptiva (efalizumab) due to PML.  Additionally, many respondents report difficulty with managed care approval for Stelara.  Respondents were divided about whether the need for a healthcare provider to administer Stelara is an advantage or disadvantage.

The majority of dermatologists expect to be using Stelara in the next six months, although 22 percent report that they will wait at least a year before initiating trial in their patients.  Overall, Stelara is expected to see significant increases in market share in the next six months, primarily off-setting Amgen/Wyeth's Enbrel and Abbott's Humira, the two most entrenched biologics for psoriasis.

The final wave of this report will be fielded in April with the results published in May and will assess product uptake at the six month mark.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends' publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. BioTrends Research Group, Inc. is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources, Inc. consists of two business units. The Medical Technology business unit includes Millennium Research Group, the global authority on medical device market intelligence. The Biopharma business unit consists of six companies: Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries; BioTrends Research Group, Inc., a provider of syndicated and custom market research to pharmaceutical manufacturers; Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues; Fingertip Formulary, the leading provider of access to and insight into formulary data in the United States; HealthLeaders-InterStudy, the leading provider of managed care market intelligence; and Manhattan Research, the leading provider of access to physician and consumer opinions on the global healthcare market. For more information, please visit www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.